Michael T Tetzlaff

33PUBLICATIONS
38CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersLiquid biopsiesMolecular targetsTe mana tāne (male status)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jan 18, 2026
Bispecific Dual-Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients.

Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya

|Jan 06, 2025
Genomic and Transcriptomic Profiling of Digital Papillary Adenocarcinomas Reveals Alterations in Matrix Remodeling and Metabolic Genes.

Erol Can Bayraktar, Phyu P Aung, Pavandeep Gill

|Mar 06, 2024
Spitz melanocytic neoplasms with MLPH::ALK fusions: Report of two cases with previously unreported features and literature review.

Haneen T Salah, Richard K Yang, Sinchita Roy-Chowdhuri

|Jan 11, 2024
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.

Woo Cheal Cho, Rayan Saade, Priyadharsini Nagarajan

|Jul 03, 2023
Telomerase reverse transcriptase immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma.

Woo Cheal Cho, Wen Li, Jun Gu

|May 07, 2023
Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells.

Mario L Marques-Piubelli, Riyad N H Seervai, Kumaran M Mudaliar

Pageof 6

Frequent Collaborators

25 joint publications

Carlos Torres-Cabala

23 joint publications

Priyadharsini Nagarajan

21 joint publications

Phyu P Aung

15 joint publications

Victor G Prieto